Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Opioid drug

This page shows the latest Opioid drug news and features for those working in and with pharma, biotech and healthcare.

Trevena gets second go at FDA approval for pain drug

Trevena gets second go at FDA approval for pain drug

The FDA has set a date of 7 August to complete its review of the marketing application for the intravenously-administered drug, a mu-opioid receptor agonist which is billed as ... the risk of respiratory and gastrointestinal side effects seen with other

Latest news

  • Mallinckrodt reaches tentative $1.6bn opioid settlement Mallinckrodt reaches tentative $1.6bn opioid settlement

    Mallinckrodt’s speciality US generics business – which includes its opioid drug franchise – will file for chapter 11 bankruptcy protection as part of the wide-scale agreement. ... We recognise the opioid crisis is a tremendously complex public

  • US states reject drug distributors’ opioid settlement US states reject drug distributors’ opioid settlement

    At least 21 US states have rejected an $18bn proposal by the ‘big three’ pharma wholesalers to settle opioid litigation, according to a Wall Street Journal report. ... to negotiating a deal that would “provide relief to communities impacted by the

  • FDA committee rejects Intellipharmaceutics’ opioid drug Aximris FDA committee rejects Intellipharmaceutics’ opioid drug Aximris

    Verdict closely follows rejection of Nektar’s opioid analgesic. The FDA’s Anesthetic and Analgesic Committee has rejected yet another opioid drug – this time Intellipharmaceutics’ extended-release oxycodone tablet Aximiris. . ... Oxycodone is

  • Nektar’s opioid analgesic slammed with FDA panel rejection Nektar’s opioid analgesic slammed with FDA panel rejection

    Panelists unanimously rejected use of the chronic back pain drug. Nektar Therapeutics has been hit with a unanimous FDA panel rejection of its opioid painkiller, over concerns of drug abuse and ... The application for the drug – NKTR-181 – was

  • MD Anderson exec Stephen Hahn to be nominated FDA commissioner MD Anderson exec Stephen Hahn to be nominated FDA commissioner

    During his time leading the FDA, Sharpless has driven progress on a number of core issues including lowering drug prices and tackling the epidemic of youth use of tobacco products. ... If he does become the agency’s next leader, he will have his hands

More from news
Approximately 1 fully matching, plus 35 partially matching documents found.

Latest Intelligence

  • As the opioid crisis grabs the headlines, the search for safe treatments continues As the opioid crisis grabs the headlines, the search for safe treatments continues

    Tackling the global crisis of addiction is not a labour for the faint-hearted. Rising levels of drug use are barbed with the complexities of opioid dependence and wreathed with the ... It is hardly the easiest climate in which to market an opioid-based

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    CAM2038 is an injectable solution that slowly releases buprenorphine – the most common drug used to treat opioid addiction – into the body, eliminating the need for daily dosages as well as the ... Compared with a similar treatment marketed by

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....

Quick links